NeuroSense Therapeutics Ltd.(NRSN)Earnings, Financials & Key Ratios
NRSN•NASDAQ
Price updated Jun 23, 2026
AboutNeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.Show more
- Revenue$0
- EBITDA-$11M-12.0%
- Net Income-$11M-9.0%
- EPS (Diluted)-0.44+20.0%
- ROE-2174.98%+12.2%
NRSN Key Insights
NeuroSense Therapeutics Ltd. (NRSN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 31.5% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 37.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NRSN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NRSN Price & Volume
NeuroSense Therapeutics Ltd. (NRSN) stock price & volume — 10-year historical chart
Loading chart...
NRSN Growth Metrics
NeuroSense Therapeutics Ltd. (NRSN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2.74%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.57%
Return on Capital
10 Years-580.51%
5 Years-712.55%
3 Years-1101.46%
Last Year-2024.66%
NRSN Peer Comparison
NeuroSense Therapeutics Ltd. (NRSN) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRTA | 499.97M | 9.55 | -2.11 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ACIU | 249.35M | 2.45 | -2.83 | -86.92% | -19.72% | -101.76% | 0.10 | |
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 ANVS | 34.23M | 1.74 | -1.24 | -318.08% | ||||
 IONS | 12.56B | 75.99 | -31.93 | 33.87% | -30.87% | -58.57% | 5.35 | |
 BIIB | 29.11B | 197.19 | 22.33 | 1.39% | 13.92% | 7.55% | 0.38 | |
 CLVT | 1.23B | 1.93 | -6.43 | -3.97% | -5.62% | -2.81% | 0.92 | |
 PTCT | 6.81B | 82.13 | 10.56 | 114.51% | -22.58% |
Compare NRSN vs Peers
NeuroSense Therapeutics Ltd. (NRSN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NRSN Income Statement
NeuroSense Therapeutics Ltd. (NRSN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 89K | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -89K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | 100% | - | - | - |
Operating Expenses | 1.24M | 2.89M | 5.59M | 13.46M | 12.05M | 9.9M | 11.09M | 8.57M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 337K | 393K | 2.5M | 7.05M | 4.78M | 4.2M | 4.86M | 3.82M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 898K | 2.5M | 3.08M | 6.42M | 7.27M | 5.7M | 6.23M | 4.75M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -1.24M▲ 0% | -2.89M▼ 133.8% | -5.59M▼ 93.5% | -13.55M▼ 142.6% | -12.05M▲ 11.1% | -9.9M▲ 17.8% | -11.09M▼ 11.9% | -8.57M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -133.85% | -93.46% | -142.56% | 11.09% | 17.82% | -11.95% | - |
EBITDA | 0 | -2.88M | -5.58M | -13.46M | -12.03M | -9.88M | -11.07M | -8.55M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | -93.55% | -141.1% | 10.66% | 17.86% | -12.03% | -35.54% |
D&A (Non-Cash Add-back) | 1.24M | 3K | 3K | 89K | 21K | 22K | 16K | 18.75K |
EBIT | -1.22M | -2.83M | -2.89M | -12.32M | -9.66M | -9.9M | -11.13M | -8.57M |
Net Interest Income | 13K | 61K | -1.15M | 76K | -372K | -309K | 13K | -88K |
Interest Income | 18K | 61K | 0 | 91K | 178K | 2K | 13K | 0 |
Interest Expense | 5K | 0 | 1.15M | 15K | 550K | 311K | 0 | 88K |
Other Income/Expense | 13K | 60K | 1.55M | 1.21M | 1.94M | -308K | -40K | -88K |
Pretax Income | -1.22M▲ 0% | -2.83M▼ 131.4% | -4.04M▼ 42.9% | -12.34M▼ 205.4% | -10.11M▲ 18.1% | -10.21M▼ 1.0% | -11.13M▼ 9.0% | -8.66M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -1.23M▲ 0% | -2.83M▼ 130.5% | -4.04M▼ 42.9% | -12.34M▼ 205.4% | -10.11M▲ 18.1% | -10.21M▼ 1.0% | -11.13M▼ 9.0% | -8.66M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -130.48% | -42.89% | -205.37% | 18.1% | -1.02% | -8.96% | -2.74% |
Net Income (Continuing) | -1.22M | -2.83M | -4.04M | -12.34M | -10.11M | -10.21M | -11.13M | -8.66M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.22▲ 0% | -0.51▼ 131.8% | -0.23▲ 54.9% | -1.07▼ 365.2% | -0.83▲ 22.4% | -0.55▲ 33.7% | -0.44▲ 20.0% | -0.34▲ 0% |
EPS Growth % | - | -131.82% | 54.9% | -365.22% | 22.43% | 33.73% | 20% | 28.57% |
EPS (Basic) | -0.22 | -0.51 | -0.23 | -1.07 | -0.83 | -0.55 | -0.44 | - |
Diluted Shares Outstanding | 5.45M | 5.52M | 10.86M | 11.51M | 13.64M | 18.6M | 25.48M | 25.4M |
Basic Shares Outstanding | 5.45M | 5.52M | 10.86M | 11.51M | 13.64M | 18.6M | 25.48M | 25.4M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
NRSN Balance Sheet
NeuroSense Therapeutics Ltd. (NRSN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 913K | 729K | 11.41M | 7.38M | 2.92M | 4.4M | 778K | 1.56M |
Cash & Short-Term Investments | 895K | 699K | 11.06M | 7.09M | 2.64M | 3.38M | 166K | 666K |
Cash Only | 895K | 699K | 11.06M | 3.54M | 2.64M | 3.38M | 166K | 666K |
Short-Term Investments | 0 | 0 | 0 | 3.55M | 0 | 0 | 0 | 0 |
Accounts Receivable | 18K | 30K | 178K | 131K | 166K | 164K | 33K | 847K |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | -18 | -67 | -178K | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 18 | 67 | 217K | 36K | 40K | 35K | 47K | 43K |
Total Non-Current Assets | 42K | 50K | 19K | 329K | 269K | 173K | 250K | 128K |
Property, Plant & Equipment | 7K | 13K | 19K | 306K | 247K | 150K | 228K | 105K |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 35K | 37K | 0 | 0 | 0 | 0 | 0 | 23K |
Other Non-Current Assets | 0 | 0 | 0 | 23K | 22K | 23K | 22K | 23K |
Total Assets | 955K▲ 0% | 779K▼ 18.4% | 11.43M▲ 1367.4% | 7.71M▼ 32.6% | 3.19M▼ 58.7% | 4.58M▲ 43.6% | 1.03M▼ 77.5% | 1.68M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -18.43% | 1367.39% | -32.55% | -58.69% | 43.64% | -77.53% | -30.16% |
Total Current Liabilities | 37K | 120K | 597K | 1.73M | 3.46M | 1.99M | 2.52M | 2.2M |
Accounts Payable | 23K | 55K | 39K | 498K | 1.46M | 1.16M | 799K | 1.09M |
Days Payables Outstanding | - | - | - | 2.04K | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5K | 29K | 443K | 370K | 0 | 0 | 0 | 0 |
Current Ratio | 24.68x | 6.08x | 19.12x | 4.28x | 0.84x | 2.21x | 0.31x | 0.71x |
Quick Ratio | 24.68x | 6.08x | 19.41x | 4.28x | 0.84x | 2.21x | 0.31x | 0.71x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 1.83M | 365K | 1.49M | 0 | 72K | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 147K | 73K | 0 | 72K | 19K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1.83M | 218K | 1.41M | 0 | 0 | 0 |
Total Liabilities | 37K | 120K | 2.42M | 2.09M | 4.94M | 1.99M | 2.59M | 2.2M |
Total Debt | 0 | 0 | 1.83M | 211K | 142K | 73K | 170K | 0 |
Net Debt | -895K | -699K | -9.23M | -3.33M | -2.5M | -3.31M | 4K | -666K |
Debt / Equity | - | - | 0.20x | 0.04x | - | 0.03x | - | -0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.08x |
Interest Coverage | -244.40x | - | -2.50x | -821.20x | -17.56x | -31.83x | - | -97.39x |
Total Equity | 918K▲ 0% | 659K▼ 28.2% | 9.01M▲ 1266.6% | 5.62M▼ 37.6% | -1.76M▼ 131.3% | 2.58M▲ 246.8% | -1.56M▼ 160.4% | -519K▲ 0% |
Equity Growth % | - | -28.21% | 1266.62% | -37.61% | -131.3% | 246.84% | -160.39% | -928.81% |
Book Value per Share | 0.17 | 0.12 | 0.83 | 0.49 | -0.13 | 0.14 | -0.06 | -0.02 |
Total Shareholders' Equity | 918K | 659K | 9.01M | 5.62M | -1.76M | 2.58M | -1.56M | -519K |
Common Stock | 1K | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -1.58M | -4.41M | -8.45M | -20.79M | -26.12M | -36.66M | -47.78M | -41.37M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NRSN Cash Flow Statement
NeuroSense Therapeutics Ltd. (NRSN) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -582K | -695K | -1.54M | -7.59M | -8.35M | -10.13M | -7.67M | -2K |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -19.42% | -121.44% | -392.92% | -10.12% | -21.32% | 24.31% | 0% |
Net Income | -1.22M | -2.83M | -4.04M | -12.34M | -10.11M | -10.21M | -11.13M | -8.66M |
Depreciation & Amortization | 0 | 3K | 3K | 89K | 21K | 22K | 16K | 0 |
Stock-Based Compensation | 611K | 2.06M | 4.16M | 5.11M | 1.54M | 557K | 2.14M | 557 |
Deferred Taxes | 0 | 2K | -2.72M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | -2K | 791K | -1.19M | -1.71M | 277K | -46K | 5.87K |
Working Capital Changes | 29K | 71K | 273K | 750K | 1.91M | -781K | 1.34M | 231 |
Change in Receivables | -3K | -12K | -204K | 55K | 19K | 0 | 0 | 71 |
Change in Inventory | 3K | 0 | 0 | -55K | 0 | 0 | 0 | 0 |
Change in Payables | 23K | 32K | -16K | 459K | 961K | -299K | -361K | 0 |
Cash from Investing | -26K | -9K | -17K | -3.54M | 3.47M | 1K | -8K | -7 |
Capital Expenditures | -7K | -9K | -17K | -70K | -29K | -3K | -8K | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 3K | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 29K | -6K | 4K | 0 | -7 |
Cash from Financing | 1.42M | 508K | 11.9M | 3.69M | 3.98M | 10.91M | 4.43M | 651 |
Debt Issued (Net) | 0 | 0 | 1.24M | -79K | -80K | 0 | 0 | 0 |
Equity Issued (Net) | 1.42M | 508K | 9.86M | 3.87M | 3.98M | 11.3M | 4.55M | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -3K | 0 | 800K | -96K | 80K | -391K | -121K | 651 |
Net Change in Cash | 809K▲ 0% | -196K▼ 124.2% | 10.36M▲ 5387.8% | -7.52M▼ 172.6% | -903K▲ 88.0% | 738K▲ 181.7% | -3.21M▼ 535.2% | -1.36K▲ 0% |
Free Cash Flow | -589K▲ 0% | -704K▼ 19.5% | -1.56M▼ 121.0% | -7.66M▼ 392.0% | -8.38M▼ 9.5% | -10.14M▼ 20.9% | -7.68M▲ 24.3% | -2K▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -19.52% | -121.02% | -392.03% | -9.5% | -20.94% | 24.26% | - |
FCF per Share | -0.11 | -0.13 | -0.14 | -0.67 | -0.61 | -0.54 | -0.30 | -0.00 |
FCF Conversion (FCF/Net Income) | 0.47x | 0.25x | 0.38x | 0.61x | 0.83x | 0.99x | 0.69x | 0.00x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NRSN Key Ratios
NeuroSense Therapeutics Ltd. (NRSN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -358.66% | -83.62% | -168.75% | -523.68% | -2478.16% | -2174.98% | 2720.5% |
Return on Invested Capital (ROIC) | - | - | -987.76% | - | - | - | 412.35% |
Debt / Equity | - | 0.20x | 0.04x | - | 0.03x | - | -0.00x |
Interest Coverage | - | -2.50x | -821.20x | -17.56x | -31.83x | - | -97.39x |
FCF Conversion | 0.25x | 0.38x | 0.61x | 0.83x | 0.99x | 0.69x | 0.00x |
Related:NRSN Dividend History·NRSN Revenue History·NRSN Price History·NRSN P/E History·NRSN Financial Ratios·NRSN Institutional Holders
NRSN Frequently Asked Questions
NeuroSense Therapeutics Ltd. (NRSN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NeuroSense Therapeutics Ltd. (NRSN) grew revenue by 0.0% over the past year. Growth has been modest.
NeuroSense Therapeutics Ltd. (NRSN) reported a net loss of $8.7M for fiscal year 2025.
Dividend & Returns
NeuroSense Therapeutics Ltd. (NRSN) has a return on equity (ROE) of -2175.0%. Negative ROE indicates the company is unprofitable.
NeuroSense Therapeutics Ltd. (NRSN) had negative free cash flow of $0.0M in fiscal year 2025, likely due to heavy capital investments.